loading
前日終値:
$151.83
開ける:
$152.63
24時間の取引高:
326.60K
Relative Volume:
0.27
時価総額:
$15.11B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
22.85
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
-4.85%
1か月 パフォーマンス:
-3.62%
6か月 パフォーマンス:
+13.72%
1年 パフォーマンス:
+2.05%
1日の値動き範囲:
Value
$148.56
$152.63
1週間の範囲:
Value
$148.56
$159.19
52週間の値動き範囲:
Value
$122.14
$186.12

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1076)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-10-27
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
148.64 15.88B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.95 58.31B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
38.79 43.22B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
9.245 40.41B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
72.60 30.15B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
495.75 21.32B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Sep 12, 2026

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits

Sep 12, 2026
pulisher
Sep 12, 2026

Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily

Sep 12, 2026
pulisher
Sep 12, 2026

ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView

Sep 12, 2026
pulisher
Sep 10, 2026

Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia

Sep 10, 2026
pulisher
Sep 10, 2026

Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Nigeria

Sep 10, 2026
pulisher
Sep 10, 2026

Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08:35 AM - marketscreener.com

Sep 10, 2026
pulisher
Sep 09, 2026

Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan

Sep 09, 2026
pulisher
Sep 09, 2026

Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com

Sep 09, 2026
pulisher
Sep 08, 2026

Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Nigeria

Sep 08, 2026
pulisher
Sep 07, 2026

How Advancing NBI-1117567 to Phase 2 and a $10M Milestone Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st

Sep 07, 2026
pulisher
Sep 07, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 06, 2026

Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st

Sep 06, 2026
pulisher
Sep 03, 2026

Neurocrine (NBIX) director donates 1,000 shares - Stock Titan

Sep 03, 2026
pulisher
Sep 02, 2026

Neurocrine Biosciences Inc. (NBIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Sep 02, 2026
pulisher
Sep 02, 2026

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September - PR Newswire

Sep 02, 2026
pulisher
Sep 01, 2026

Resilient Neurocrine Biosciences stock holds firm as Crenessity sales surge and valuation stretches - AD HOC NEWS

Sep 01, 2026
pulisher
Aug 31, 2026

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - Yahoo Finance

Aug 31, 2026
pulisher
Aug 29, 2026

Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation - ChartMill

Aug 29, 2026
pulisher
Aug 29, 2026

Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount? - simplywall.st

Aug 29, 2026
pulisher
Aug 28, 2026

How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data - Sahm

Aug 28, 2026
pulisher
Aug 27, 2026

Neurocrine Biosciences (NBIX) Stock Looks Fairly Priced As 64% Gain Holds - Yahoo Finance

Aug 27, 2026
pulisher
Aug 26, 2026

Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition - Yahoo Finance

Aug 26, 2026
pulisher
Aug 24, 2026

Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run - simplywall.st

Aug 24, 2026
pulisher
Aug 24, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 38.67% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews

Aug 24, 2026
pulisher
Aug 22, 2026

Neurocrine Biosciences: 'House Full Of Options' - Seeking Alpha

Aug 22, 2026
pulisher
Aug 21, 2026

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Eastern Progress

Aug 21, 2026
pulisher
Aug 20, 2026

Zacks Investment ResearchGlobes - Globes - Israel Business News

Aug 20, 2026
pulisher
Aug 20, 2026

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore

Aug 20, 2026
pulisher
Aug 18, 2026

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st

Aug 18, 2026
pulisher
Aug 18, 2026

SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits

Aug 18, 2026
pulisher
Aug 17, 2026

GlobesIsrael Business News - גלובס

Aug 17, 2026
pulisher
Aug 17, 2026

Neurocrine Biosciences Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Aug 17, 2026
pulisher
Aug 17, 2026

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance

Aug 17, 2026
pulisher
Aug 17, 2026

Neurocrine Biosciences Rings the Opening Bell - Nasdaq

Aug 17, 2026
pulisher
Aug 17, 2026

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: 38.54% Potential Upside Beckons Investors - DirectorsTalk Interviews

Aug 17, 2026
pulisher
Aug 16, 2026

Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus

Aug 16, 2026
pulisher
Aug 16, 2026

S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 16, 2026
pulisher
Aug 16, 2026

Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 16, 2026
pulisher
Aug 16, 2026

14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat

Aug 16, 2026
pulisher
Aug 16, 2026

Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st

Aug 16, 2026
pulisher
Aug 15, 2026

NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Aug 15, 2026
pulisher
Aug 15, 2026

Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals

Aug 14, 2026
pulisher
Aug 14, 2026

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters

Aug 14, 2026
pulisher
Aug 13, 2026

Neurocrine Biosciences Inc (NBIX) Shares Fall 3.6% -- What GF Sc - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com

Aug 13, 2026
pulisher
Aug 13, 2026

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating - marketscreener.com

Aug 13, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.59
price down icon 0.64%
$17.02
price down icon 0.58%
RDY RDY
$12.15
price down icon 0.27%
$495.04
price down icon 0.49%
$44.74
price down icon 4.32%
大文字化:     |  ボリューム (24 時間):